40 results
8-K
EX-99.1
PSTX
Poseida Therapeutics Inc
7 Mar 24
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
4:05pm
by a decrease in clinical stage autologous programs driven by the wind-down of the Company’s clinical development activities for such programs … in internal costs related to facilities and other expenses, offset by a decrease in clinical stage autologous programs driven by the wind-down
8-K
EX-99.1
PSTX
Poseida Therapeutics Inc
9 Nov 23
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023
4:05pm
in clinical stage programs, primarily driven by the wind-down of the Company’s clinical development activities associated with its autologous programs
8-K
EX-99.1
yh78d03 vfi
8 Aug 23
Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023
4:06pm
CORRESP
atbi7 tqsf68fcn
7 Jul 23
Correspondence with SEC
12:00am
8-K
EX-99.1
7g70pyg872o
9 May 23
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023
4:06pm
8-K
EX-99.1
1rx18i1t1at2ra0o
10 Nov 22
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022
4:13pm
8-K
EX-99.1
dw3jf4fpa1wu3 63mjoq
11 Aug 22
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022
4:27pm
424B5
n7lv ma4q2oocr0ib
4 Aug 22
Prospectus supplement for primary offering
4:52pm
424B5
w9to30vbef f8exy
3 Aug 22
Prospectus supplement for primary offering
4:05pm